InvestorsHub Logo
Followers 25
Posts 1218
Boards Moderated 0
Alias Born 12/11/2008

Re: Fress post# 807

Monday, 07/06/2020 5:55:35 PM

Monday, July 06, 2020 5:55:35 PM

Post# of 36559
Fress, what's the latest word from your friend who is a "Pharma analyst at Goldman Sachs"?

You need to go back to chart school you have no idea whats coming RVVTF Phase 3 drug with very low side affects to treat large patient populations of Covid-19.Gap filled perfectly at .2003 Wave 5 Fib RVVTF price target $10.00 by end of summer. My friend is a Pharma analyst at Goldman Sachs. He says if Approval on RVVTF Bucillamine comes for Covid-19. At hits current market cap. The price valuations will between $20.00-$30.00


$RVVTF